* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Systemic Disease Straight Up…..with a Twist of Neuro! AOA’s definition of Optometry
		                    
		                    
								Survey							
                            
		                
		                
                            
                            
								Document related concepts							
                        
                        
                    
						
						
							Transcript						
					
					Systemic Disease Straight Up…..with a Twist of Neuro! Beth A. Steele, OD, FAAO Caroline B. Pate, OD, FAAO Optometry’s Meeting 2014 AOA’s definition of Optometry approved Sept 2012 Doctors of optometry (ODs) are the independent primary health care professionals for the eye. Optometrists examine, diagnose, treat, and manage diseases, injuries, and disorders of the visual system, the eye, and associated structures as well as identify related systemic conditions affecting the eye. No disclosures Driving Forces in Health Care Changes  Affordable Care Act Quality of Patient Care  Coding  Risk Adjustment  Physician Quality Reporting PREVENTION From: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) WELLNESS COMMUNITY HEALTH TREATING THE WHOLE PATIENT MEDICAL OPTOMETRY CLINICAL QUALITY MEASURES …..where do we fit in? 1 Is routine blood pressure part of your daily routine in patient care? JNC 8 – What’s New?  Threshold for treatment of BP in ages ≥60  150/90 vs. 140/90 HYPERTENSION  Approximately 65 million people in  Recommendations for initial therapy  Thiazide diuretics  ACE inh, ARBs, Ca2++ channel blockers  NOT: β‐blockers, α‐blockers, loop diuretics US  30% of population unaware  7.1 million deaths per year  “Silent Killer”  Stroke, MI, ESRD Blood Pressure Classifications and Referral Guidelines “Hypertensive Crisis” (adapted from the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure – JNC 7, 2003) Hypotensio n Systolic < 90 Diastolic < 60 normal Pre‐ Htn Stage 1 Stage 2 Stage 3 Stage 4 < 120 120‐139 140‐ 159 160‐179 180‐209 >210 < 80 80 ‐ 89 90‐99  URGENT vs. EMERGENT 100‐109 110‐119 >120 Systolic >180 Diastolic >110 (>120) Confirm within 2 months Evaluate or refer to PCP within 1 month Evaluate or refer immediately or within 1 week Evaluate or refer immediately BP 190/112  Feeling “fine”  (+) “migraine”since yesterday  Forgot his medicine today  DFE: disc edema  Denies H/A, etc  DFE: crossing changes, blot heme flame heme “Evaluate and treat immediately or within 1 week depending on clinical situations and complications.”  Systemic symptoms  Ocular findings Meetz RE, Harris TA. The optometrist's role in the management of hypertensive crises. Optometry. 2011 Feb;82(2):108-16. Hypotension Same BP – 2 different situations BP 190/112  JNC 7  Low Blood Pressure  Systolic < 90  Diastolic < 60  Poor perfusion of oxygen and nutrients to vital organs  Common symptoms = fatigue, dizziness, fainting, confusion  Risk of ocular manifestations 2 Proper methods = Accurate Results Vitals Station Meaningful Use Patient Vital Signs  Temperature – 96.4ͦ ‐ 99.1ͦ  Blood Pressure – <120/<80  Respiration Rate – 20 breaths/min  Heart Rate – 50‐90bpm  Others  Weight/height BMI<25  Pain Stage 1 (Core Obj #8) Record and chart changes in vital signs:  Height  Weight  Blood pressure  Calculate and display BMI  Plot and display growth charts (BMI) for ages 2‐20 years Stage 2 (Core Obj #4) Age (≥3) only For more than 50% of all unique patients age ≥2, BP, height and weight are recorded as structured data Stage 1– Core Quality Care Measures (Core Objective #10) HTN ‐ BP measurement BMI screening and follow‐up (alt) Weight assessment and counseling for children and adolescents Stage 2 – Quality Measures are separated from Meaningful Use 0-20 More than 80% Now with EOM involvement….?? BP 190/112  Feeling “fine”  Forgot his medicine today  Denies H/A, etc  DFE: crossing changes, blot heme http://cim.ucdavis.edu/EyeRelease/Interface/TopFrame.htm 2014 – must report on new CQMs CMS 22v1 ‐ Preventive Care and Screening: Screening for High Blood Pressure and Follow‐Up Documented CMS69v1 ‐ Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow‐Up 3 Cranial Nerve III Palsy  EOMs – SO and LR are unopposed  Levator  Parasympathetic pupillary fibers  Will NOT constrict with WEAK pilocarpine Etiology – CN III Palsy  Pain or pupil involvement  Lesions that involve the pupil are most likely compressive in nature (80%  Emergency imaging  Patient may have headache or other neuro signs  NO pain or pupil involvement  77% that spare pupil are vasculopathic  Resolution usually within 3 months  Follow closely  Imaging? Kanski. Clinical Ophthalmology, 4th Ed double vision double vision • Head injury 3 months ago – Imaging in ER all negative • Vertical diplopia; worse when looking down – Right head tilt • Medications – Atenolol, lisinopril/HCTZ, Trazodone, WellButrin, Cymbalta • Smokes ½ day :/ Double Maddox Rod??  MR over both eyes  Place small vertical prism over one eye 1⁰ gaze – note head posture Under‐action LSO  Cyclodeviated eye will report a “tilted” line  Rotating MR toward the torsion of the eye will straighten image of line 4 Torsion noted on DFEs! SO Palsy  Very common with closed head trauma  Blunt force to frontal area  May be least likely of EOM palsies to have underlying etiology, but….  Microvascular disease  Brain abnormality  Imaging, careful follow‐up VI Palsy – Pearls Isolated EOM palsies  Incomitant ET worse when gaze towards paretic eye  Lab testing  Microvascular disease, Giant Cell Arteritis  Compensatory head turn away from paretic eye  distance > near …. Think neuro cause  Imaging  Tumor, aneurysm  Children  Frequently acquired and transient  Trauma, Tumor, hydrocephalus  Adults  22% ‐ brain tumor  26% = idiopathic  Do not assume true isolation! Summary of CN Functions and Testing Adapted from Muchnick, B. Clinical Medicine of Optometric Practice, 2nd Ed. Cranial Nerve I – Olfactory Test CN Tes ng → involvement of VII and VIII Identify odors II - Optic Visual acuity, visual field, color, nerve head III - Oculomotor Physiologic “H” and near point response IV – Trochlear Physiologic “H” Summary Corneal of Cranial Nerve Functions and Testing reflex; clench jaw/palpate V - Trigeminal (Adapted from Muchnick, B. Clinical Medicine in Optometric Practice, 2nd ed.) Light touch comparison VI - Abducens Physiologic “H” VII - Facial Smile, puff cheeks, wrinkle forehead, pry open closed lids VIII - Vestibulocochlear Rinne test for hearing, Weber test for balance IX - Glossopharyngeal Gag reflex X - Vagus Gag reflex XI – Accessory Shrug, head turn against resistance XII - Hypoglossal Tongue deviation C 5 Ramsay Hunt Syndrome  Varicella Zoster Virus reactivation in geniculate ganglion  Symptoms: Pain, hearing loss, dizziness, tinnitus, nausea, vertigo  Treatment with oral antivirals + oral prednisone  Protect the cornea!  Poorer prognosis than Bell’s palsy  Recurrences are rare Updated Clinical Practice Guidelines: Bell’s Palsy  Recommends prescribing oral steroids within 72 hours of symptom onset for patients with Bell’s palsy 16 years and older  Recommends offering oral antiviral therapy in addition to oral steroids within 72 hours of symptom onset  Other recommendations:  Careful history and physical exam to rule out other causes  Inclusion of eye care for impaired lid closure  Against routine laboratory testing and imaging for new onset Bell’s palsy Baugh R, Basura G, Ishii L, et al. Clinical practice guideline: Bell’s Palsy. Otolaryngol Head Neck Surg 2013; 149(suppl 3) S1-S27. “Blood work‐up”….tests driven by differentials  CBC with differential  Chem 7  Lipid Profile  C‐Reactive Protein  ESR  Uveitis testing Complete Blood Count  White Blood Count (WBC)  Differential White Blood Count (Diff)  Red Blood Count (RBC)  Hematocrit (Hct)  Hemoglobin (Hb)  Platelet Count (PLT)  Red Blood Cell Indices:  Mean Corpuscular Volume (MCV)  Mean Corpuscular Hemoglobin (MCH)  Mean Corpuscular hemoglobin Concentration (MCHC) Chem 7 / Basic Metabolic Panel 1. Creatinine 2. Blood urea nitrogen (BUN) 3. Glucose  Screens for  Kidney disease  Liver Disease  Diabetes and other blood sugar disorders 4. Carbon dioxide 5. Chloride 6. Sodium electrolytes 7. Potassium 8. (Sometimes Calcium) 6 NON‐GRANULOMATOUS CAUSE OF UVEITIS Etiology 46 year old AA female  Recurrent and recalcitrant uveitus  KPs  Conjunctival granuloma  ROS Sex Race History Questions Lab Tests Ankylosing spondylitis M>F W>B Lower back pain? HLA‐B27, back x‐ray, RF (‐), ESR (+) Reactive arthritis (formerly Reiter’s) M>F W>B Arthritis? Pain when urinating? HLA‐B27, ESR (+), ANA (‐). RF (‐), Urethral swab Juvenile RA F>M W=B Knee pain? Knee x‐ray, RF (‐), ANA (+) Lyme disease M=F W=B Rash? Fever? Recent tick bite? ELISA + for antispirochetal antibody titer Herpetic Disease M=F W=B Skin vesicles? Skin biopsy/culture, Consider HIV testing Crohn’s M=F W=B Stomach pain? GI workup, Endoscopy, HLA‐B27 GRANULOMATOUS CAUSE OF UVEITIS  Resp: “cough” Sarcoidosis F>M Syphillis M=F Tuberculosis M=F B>W Cough? Chest X‐ray, ACE (elevated), Lung biopsy, Serum Lysozyme W=B Rash? Fever? Chancre? FTA‐ABS VDRL or RPR W=B Cough? PPD Chest X‐ray Table adapted from: Muchnick B. Clinical Medicine in Optometric Practice 2008 Vs. Point of Care Laboratory Testing…. Procedure CPT Code Reimbursement Erythrocyte Sed Rate 85652QW $4.96 Chlamydia Culture 87110QW $27.00 Dipstick Urinalysis 81002QW $4.37 Pregnancy Urinalysis 81025QW $8.74 Glucometry 82962QW $3.42 HbA1C 83037QW $13‐18 AdenoPlus Adenovirus 87809QW Detection $17.52 InflammaDry 83516QW $18.36 Tear Lab Osmolarity 83861QW $24.30 Sjo Test 36416 (finger stick) + CPT codes for lab tests run What’s New in Point of Care Testing??  InflammaDry  MMPs in tears  Much like AdenoPlus  Tests for classical and new makers for Sjögren’s  Kits are free  Requires finger stick In‐office Blood Glucometry and A1C  Blood glucose  reading in ~5 seconds  A1C Now+® (CHEK Diagnostics)  99% lab accuracy  Results in 5 minutes  www.a1cnow.com  Cost: ~ $12.00/test (available in sets of 10 or 20)  cleared by FDA for home use Genetically classifying AMD patients?  Based on known factors in AMD pathogenesis 1. the complement system 2. cholesterol metabolism 3. extracellular matrix remodeling .  Simple cheek swab  No CLIA certification required  Macula Risk PGx  RetinaGene AMD (Nicox) 4. oxidative stress 7 CLIA Certificate of Waiver (CMS‐116)  42 AA female  FHx glaucoma  IOP 21, 20 10‐2 5 months later – patient reporting arm weakness 8 MRI – Imaging of Choice  T1 weighted imaging ‐‐ Fat is bright, fluid is dark  Quicker capture → Better resolution  Add Fat suppression – will enhance ON  T2 weighted – fluid is bright  Detects edema  FLAIR ‐‐ Fluid‐attenuation inversion recovery  CSF appears dark, while inflammatory fluid/edema is bright  DWI – Diffusion Weighted Imaging  can be added if ischemic event is suspected If it’s a tumor…. If it’s a stroke….  MRI  MRA  CT  Angiogram The terrifying truth about diabetes… By 2050….. 1 in 3 adults will be diabetic WHY???? 9 The terrifying truth …  86% of Type 1 diabetics 40% of Type 2 diabetics have clinically evident diabetic retinopathy Current ADA Diagnostic Criteria for DM  HbA1c ≥ 6.5%  Random plasma glucose ≥ 200mg/dL + symptoms (polyuria, thirst, wt loss, blurred vision)  1/3 to ½ of diabetic patients do not receive an annual eye examination  Fasting plasma glucose ≥ 126mg/dL  OGTT 2 hour post‐load glucose ≥ 200mg/dL  By 2050, the number of patients with diabetic retinopathy will triple American Diabetes Association. Standards of Medical Care in Diabetes 2014. Related Conditions  Pre‐Diabetes  Impaired glucose tolerance  A1C of 5.7% ‐ 6.4%  Fasting BS of 100‐125 mg/dl  OGTT 2 hour blood glucose of 140 ‐ 199mg/dl  Metabolic Syndrome – 25% of population  Pre‐diabetic  Abdominal obesity  HTN  High cholesterol AOA Clinical Practice Guidelines  January, 2014  Evidence‐based vs. “consensus‐based”  Stimulated by the new process established by the Institute of Medicine (IOM) of the National Academy of Sciences – evidence and outcome driven  576 papers reviewed, critiqued and referenced by 18 peer experts AOA Clinical Practice Guidelines  Covers the basics…  When to refer undiagnosed patient with symptoms to PCP  How often to perform DFE  Recommendations for f/u of macular edema  Treatment of neovascularization Communicate with patient’s PCP regardless of retinopathy status  And beyond…  Use of OCT  Rapid‐acting carbohydrates – need in office for hypoglycemic events 10 After all these years….  Diabetic Retina Study (DRS) – 1971‐75  Efficacy and timing for PRP and focal laser to prevent vision loss  Early Treatment Diabetic Retinopathy Study The Use of OCT  Detection and monitoring response to treatment (ETDRS) – 1979‐90  Efficacy and timing for PRP and focal laser to prevent vision loss  Classification of stages of retinopathy and CSME  Routine macular OCT NOT indicated  Central macular thickness – not the only factor in the return of visual function Management of DR Pregnancy and Diabetic Retinopathy  Main risk factor for DM  PRP  May be considered for severe NPDR when high risk of progression  Vitrectomy  The sooner the better for vitreous hemes  Small gauge – less complications, better outcomes  ERM, VMT  Macular edema  Anti‐VEGF +focal laser when central and 20/30 or worse 2014 ADA Guidelines For pregnant patients with pre-existing diabetes (Type I or II): worsening during pregnancy is baseline severity of diabetic retinopathy  2.5 x increased risk  Recommend A1C <6% in pregnant patients with pre‐existing Type 1 or 2 DM Gestational Diabetes  5‐10% of pregnancies  Diagnosed 2nd – 3rd trimester •DFE once per trimester •Retinopathy counseling  Glucose tolerance typically returns to normal 6 weeks post‐partum  Due to short/temporary duration → GDM does not typically lead to development of diabetic retinopathy 11 Earlier Detection ??  autofluorescence of lens  AGEs Crystalline lens autofluorescence  Advanced glycation end products (AGEs)  Highly correlated with uncontrolled blood glucose  An increase in AGEs is linked to autofluorescence  Linked to diabetic cataract formation  Present up to 7 years earlier than other diabetic complications  Identification of risk factors for retinopathy?  Closer follow‐up? Creativity in blood glucometry… Patient Education  ABCs of diabetes A –A1C /blood glucose is “individualized” B –140/80 or less C –LDLs 100 or <70 if CVD S – smoking increases risk of retinopathy  Weight loss  Exercise – 150 min per week Nutrition for Diabetics  Dietary Advice  Glycemic index  Supplements  Benfotiamine  Pycnogenol Nutritional Supplementation??  Believed to  Control glucose levels  Inhibit diabetic induced retinal oxidative damage  Protective effect against retinopathy  Some include:  Vitamin D, E  Benfotiamine  Pycnogenol 12 Ocular signs of carotid artery disease  Ocular Hypoperfusion  Hollenhorst Plaque  CRAO  Amaurosis Fugax  4/5 strokes are causes by athersclerotic disease at carotid bifurcation  leading causes of death in US  1/3 of cases are fatal  Survivors usually have irreversible damage Landwehr P, et al Atypical/differentials?? Pearls and Prognosis  Other clues  Attenuated arterioles  Look for (+)SAP  Or….. How easily can you collapse the arterial tree?  5 year mortality rate – 40%  90% blockage – CRA perfusion pressure ↓ 50% Carotid Bruit  Usually ≥70% blockage before ocular manifestations 13 Management of intra‐arteriolar plaque  Acute care  Symptoms?  Antiplatelets? Blood thinners?  Eliquis (apixaban)  Determining and Caro d Artery Dissec on → Horner’s Syndrome  3rd order neuron defect along sympathetic pathway  Imaging treating underlying etiology  Doppler  EKG/Angiography http://www.cmaj.ca Caro d Artery Dissec on → Horner’s Syndrome  Dx of Horner’s  10% cocaine – will NOT dilate  0.5% apraclonidine – WILL dilate  1% phenylephrine – WILL dilate  1% hydroxyamphetamine –  Helps to localize lesion  What else can help us localize the lesion????  This patient has a 3rd order neuron lesion – sweating unaffected Atrial Fibrillation  Most common cardiac arrhythmia  Increased risk of stroke and MI  Many undiagnosed  History  ECG (no P wave)  Linked to retinopathy in diabetics *Starting proven medications and therapy within 24 hours of symptom onset reduces the risk of having a stroke within 3 months by 80% Dennis M, et. al. Prognosis of transient ischemic attack in the Oxfordshire Community Stroke Project. Stroke. 1990 Jun; 21(6): 848-53. Rothwell PM et al. Effect of urgent treatment of transient ischemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007; 370(9596): 1432-42. 14 Risk of stroke after TIA Johnston WC, Rothwell PM, Nguyen‐Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007; 369: 283‐292.  Consider your risk factors in patients with TIA!  ABCD2 rule  Age>60 (1 point)  BP ≥140/90 on first assessment after TIA (1 point)  Clinical features of TIA (unilateral weakness=2 points or speech impairment without weakness=1 point)  Duration of TIA (≥60 minutes=2 points; 10‐59 minutes=1point)  Diabetes (1 point) Blood in the retina…. What else can cause blood in the retina? End Stage Renal Disease  Medical History  Recent cough?  Severe kidney disease?  Anemia?  Blood dyscrasias?  Social/employment history  Heavy lifting Factor V Leiden??? What’s that?!!  Factor V – clotting protein  genetic mutation: ↑clotting in veins  Caucasians of European descent  Often undiagnosed, however….  Complications  Miscarriage and clots in pregnancy  deep vein thrombosis  pulmonary embolisms  CRVO Fegan CD et al, Eye (2002) 15 Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy Plaquenil ‐‐ What to look for on OCT… Marmor MF, et al. Ophth Feb 2011.  Risk of toxicity increases sharply towards 1% after 5‐7 yrs of use, or cumulative dose of 1000 g HCQ  Initial baseline exam, then annual screenings after 5 years Marmor MF, et al. Ophthalmology. AAO Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy. Feb 2011.  Screening:  Regular exams with DFE  10‐2  SD OCT, FAF or mfERG  Outer retina  Loss of IS/OS line (PIL); thinning of PR layer  Thickening of outer band of RPE  Inner retina  Parafoveal thinning of GCL, IPL  1.0mm (but not 0.5mm) from foveal center But WAIT!!  10% of patients with a ring scotoma do NOT show damage with SD‐OCT! Coding for high risk meds • Code systemic disease which is the reason for the medication Marmor MF, Melles RB. Ophthalmology. 2014 Jan 15. pii: S0161‐ 6420(13)01174‐3. doi: 10.1016/j.ophtha.2013.12.002. Disparity between Visual Fields and Optical Coherence Tomography in Hydroxychloroquine Retinopathy. – Long term (current) use of high risk medication– V58.69 – SLE – 695.4 • ICD‐10 codes…..October 1,2015!!! – Z79.899 : “other long term (current) drug therapy” Talc Retinopathy Differential Diagnoses of refractile deposits in the retina  Drug Related 1. 2. 3. 4. 5. 1. Tamoxifen 2. Canthaxanthine 3. Nitrofurantoin 4. Ritonavir 5. Talc  Embolic Diseases 1. 2.  Primary Ocular Disorders 1.  Genetic Disorders 1. Primary Hyperoxaluria 2. Cystinosis 3. Hyperornithinemia 4. Sjögren‐Larsson Syndrome 1. Calcium emboli 2. Cholesterol emboli 2. 3. 4. Calcified macular drusen Idiopathic parafoveal telangiectasis Bietti’s crystalline dystrophy Longstanding retinal detachment 16  Optical coherence tomography (both time domain and spectral domain) confirms talc particles are localized to the inner retinal layers (containing retinal vasculature)  NFL, INL, Clinical Management  Patients without retinal ischemia, NFL defects, and without ongoing IV drug use should be photodocumented and monitored on an annual basis with visual fields  Consider referral to PCP to monitor for small vessel disease  Talc retinopathy has been associated with pulmonary talcosis, which can result in respiratory dysfunction, pulmonary HTN, and possibly death choriocapillaris From: Vinay A. Shah, et al. Talc Retinopathy. Ophthalmology. 2008: 115(4). 755 - 755.e2 http://dx.doi.org/10.1016/j.ophtha.2007.10.043 PREVENTION WELLNESS COMMUNITY HEALTH TREATING THE WHOLE PATIENT MEDICAL OPTOMETRY CLINICAL QUALITY MEASURES …..where do we fit in? Relate your advice to relevant ocular findings  Weight Loss  Smoking Cessation  Supplementation  Vitamin D  Advise with caution….  AMD patients  Blood thinners 17